Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alacris Theranostics and GlaxoSmithKline (GSK) have signed an agreement to use ModCell system in early stage cancer research.
Subscribe to our email newsletter
Max Planck Institute for Molecular Genetics developed the ModCell system and licensed it to Alacris.
GSK will provide pre-clinical biology data from oncology research to Alacris, which will apply the system for drug stratification.
The in silico effect of the inhibitor will be determined, by Alacris’ Systems Biology model, in its virtual clinical trial system.
Cancer cell lines and high probability cancers that respond to the inhibitor can be determined based on whole genome and transcriptome data integrated in the Alacris’ cancer model ModCell.